文献速递膀胱癌与上尿路尿路上皮癌

上尿路尿路上皮癌内镜保肾手术后复发与进展风险模型

Risk of Recurrence and Progression After Endoscopic Kidney-sparing Surgery for Upper Tract Urothelial Carcinoma.
PubMed 文献 · Eur Urol Oncol · 2026-01-24

基于358例接受内镜保肾手术的上尿路尿路上皮癌患者的多中心回顾数据,分析223例,中位随访39个月,48%复发、17%进展。构建了预测无复发生存和无进展生存的评分系统,并划分三个风险组,5年累积复发率37%-70%,进展率4%-30%。

要点

  • 同步膀胱癌、活检高级别、多灶性UTUC和UTUC病史是无复发生存的预测因子。
  • 同步膀胱癌、活检高级别、肿瘤≥2 cm和尿脱落细胞学阳性是无进展生存的预测因子。
  • 模型区分度中等(C指数0.60-0.64),低、中、高危组5年复发率37%、58%、70%,进展率4%、18%、30%。

核心结论

  • 提出一种新的UTUC内镜保肾手术后风险分层模型,包含复发和进展的关键预测因子,并识别出结局不同的中危UTUC类别。

研究设计与样本

  • 回顾性多中心数据库研究,2010-2021年358例接受根治性意图内镜保肾手术的UTUC患者,最终分析纳入223例。

主要发现

  • 中位随访39个月,106例(48%)复发,37例(17%)进展。
  • 无复发生存预测因子:同步膀胱癌(HR 1.52)、活检高级别(HR 1.38)、多灶性UTUC(HR 1.12)、UTUC病史(HR 1.43)。
  • 无进展生存预测因子:同步膀胱癌(HR 1.44)、活检高级别(HR 1.38)、肿瘤大小≥2 cm(HR 1.23)、细胞学阳性(HR 1.64)。
  • 5年无复发生存C指数0.60,5年无进展生存C指数0.64。

关键数值与推荐

  • 低、中、高危组5年累积复发率分别为37%、58%、70%。
  • 低、中、高危组5年累积进展率分别为4%、18%、30%。

临床怎么用

  • 该模型可用于UTUC内镜保肾手术后的风险分层,辅助个体化随访和临床决策。

局限性

  • 缺乏外部验证。
  • 内镜保肾手术队列存在异质性。
  • 随访时间有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Our aim was to identify key prognostic factors for recurrence and progression of upper tract urothelial carcinoma (UTUC) after endoscopic kidney-sparing surgery (eKSS), and to provide a reliable, easy-to-use, risk stratification model. METHODS: We used data from a retrospective multicenter database for 358 patients with UTUC who underwent eKSS with curative intent between 2010 and 2021. A scoring system to predict recurrence-free survival (RFS) and progression-free survival (PFS) was developed using regression analyses. The discriminative ability of the score was estimated using the C index. KEY FINDINGS AND LIMITATIONS: The analysis included 223 patients, of whom 106 (48%) had recurrence and 37 (17%) had progression at median follow-up of 39 mo. Scoring systems were created that included synchronous bladder cancer (BCA; hazard ratio [HR] 1.52), high grade at biopsy (HR 1.38), multifocal UTUC (HR 1.12), and history of UTUC (HR 1.43) as factors for RFS, and synchronous BCA (HR 1.44), high grade at biopsy (HR 1.38), size ≥2 cm (HR 1.23), and positive cytology (HR 1.64) as factors for PFS. The C index was 0.60 for 5-yr RFS and 0.64 for 5-yr PFS. Three risk groups for each model were identified. The 5-yr cumulative incidence rates for the low-risk, intermediate-risk, and high-risk groups were 37%, 58%, and 70% for recurrence, and 4%, 18%, and 30% for progression, respectively. Limitations include the lack of external validation, a heterogeneous eKSS cohort, and limited follow-up. CONCLUSIONS AND CLINICAL IMPLICATIONS: We propose a novel risk stratification model for patients with UTUC treated with eKSS that includes key predictors for recurrence and progression and an intermediate-risk UTUC category with distinct outcomes.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Gallioli A, Di Bello F, Zattoni F, et al. Risk of Recurrence and Progression After Endoscopic Kidney-sparing Surgery for Upper Tract Urothelial Carcinoma. Eur Urol Oncol. 2026. PMID: 41582026. doi:10.1016/j.euo.2026.01.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。